Latest ToleroMune(R) Stories

OXFORD, England and SAN ANTONIO, February 25, 2013 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune(R) cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment. The results were presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and...

OXFORD, England, September 27, 2012 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the publication of positive phase II results with its ToleroMune(R) cat allergy treatment in the Journal of Allergy and Clinical Immunology (JACI). The results show that cat allergy patients who received four doses of ToleroMune(R) treatment over 12 weeks maintained a significantly greater improvement in symptoms one year after the start...